Genmab A/S · OMXCOP:GMAB
Genmab A/S — FY2008 Earnings Presentation
6 slides from Genmab A/S's earnings presentation, 2009
Slide 1: Results for 12 months ended December 31, 2008
Results for 12 months ended December 31, 2008
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, inclu
Slide 3: Key Data
Key Data 12 Months ended December 31, 2008 2008 2007 2008 2007 DKK millions USD millions * Revenue 745 530 141 100 Net Loss (965) (383) (183) (73) Cash and marketable securities Balance at end of the period 1,762 3,693 333 699 Decrease in 2008 1,931 366 Manufacturing employees 158 - 158 - All Other
Slide 4: Income Statement
Income Statement 12 Months ended December 31, 2008 2008 2007 2008 2007 DKK millions USD millions * Revenue 745 530 141 100 Cost of Sales (48) - (9) - R&D Costs (1,423) (849) (270) (161) G&A Expenses (144) (118) (27) (22) Operating Expenses (1,615) (967) (306) (183) Operating Loss (870) (437) (165) (
Slide 5: Highlights & Subsequent Events
Highlights & Subsequent Events • Clinical trial progress – Positive ofatumumab Phase III CLL data – RA patients in Phase II ofatumumab study achieved long lasting results – Completed recruitment in 3 ofatumumab studies • Manufacturing – acquired MN antibody facility • Initiated new studies – 4 ofatu
Slide 6: Guidance for 2009
Guidance for 2009 DKK USD Millions Millions 5.285 * Revenue 1,200 227 Operating Expenses 1,600 303 Operating Loss (400) (76) Cash Burn (500) (95) Cash at end of Year* 1,250 237 * USD 1.00 = DKK 5.285 (Danish Central Bank spot rate on December 31, 2008) * Cash, cash equivalents and marketable securit